<DOC>
	<DOCNO>NCT00827892</DOCNO>
	<brief_summary>Intracerebral hemorrhage ( ICH ) devastate disease le 20 % survivor independent 6 month . There currently approve treatment ICH show improve outcome . In effort develop new treatment ICH , research focus different aspect ICH treatment yet evaluate : enhance absorption blood clot medication .</brief_summary>
	<brief_title>Safety Pioglitazone Hematoma Resolution In Intracerebral Hemorrhage</brief_title>
	<detailed_description>Intracerebral hemorrhage ( ICH ) remain devastating disease current treatment option lag far behind ischemic stroke . Current treatment effort ICH target towards primary brain injury cause hemorrhage growth hematoma . This research target secondary injury cause persistence toxic blood degradation product brain parenchyma . Based preclinical work lab , peroxisome proliferator activate receptor-gamma ( PPARγ ) , member nuclear receptor superfamily , represent possible target treatment ICH aim promote hematoma absorption , limit pro-inflammatory response , protect salvageable tissue damage produce persistence toxic blood degradation product . Our primary specific aim ass safety PPARγ agonist , pioglitazone ( PIO ) increase dose 3 day , administered patient ICH within 24 hrs symptom onset . Secondarily , aim determine duration treatment PIO hematoma/edema resolution ICH . Lastly , aim determine whether speed hematoma/edema resolution ICH represent radiographic biological marker activity correlate clinical outcome treatment effect PIO . The ultimate purpose provide baseline data aspect ICH previously target treatment effort develop safe effective treatment strategy may practical applicable specialize stroke center community hospital .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hematoma</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1. age 1880 year 2. clinical presentation spontaneous ICH 3 . CT scan compatible spontaneous ICH 4 . Time PIO treatment ≤ 24 hour symptom onset 5 . GCS ≥ 6 initial presentation OR improvement GCS ≥ 6 within time frame enrollment 6 . Hematoma volume ≥ 5cc initial head CT. 1 . Participation another investigational trial previous 30 day 2 . Patient undergo surgical evacuation ICH ( ventriculostomy NOT exclude patient ) 3 . Inability undergo neuroimaging MRI ( e.g . pacer , recent stent , inability lie flat ) . If patient mild claustrophobia agitation amenable mild sedation ( 12mg lorazepam IV 510mg diazepam PO ) , may consider enrollment . If , however , patient severe claustrophobia agitation , consider enrollment . 4 . GCS &lt; 6 5 . Baseline mRS ≥ 3 6 . Primary intraventricular hemorrhage 7 . ICH due coagulopathy ( PT &gt; 15 sec INR &gt; 1.3 , PTT &gt; 36 ) trauma 8 . History intolerance allergy TZD 9 . Thrombocytopenia : platelet count &lt; 100,000 10 . Clinically significant hepatic disease demonstrate history , clinical exam ( ascites , varix ) , laboratory finding ( LFTs ≥ 2x normal , coagulopathy describe ) 11 . Comorbid condition , opinion investigator , likely complicate therapy include limited : 1 . A history NYHA class II , III , IV CHF 2. clinically significant arrhythmia 3. end stage AIDS 12 . Pregnancy determine urine pregnancy test 13 . Severe anemia presentation : hemoglobin &lt; 10 g/dL hematocrit &lt; 30 % 14 . Malignancy ( history active ) 15 . Patient unlikely , investigator 's opinion , complete study return followup visit reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Intracerebral Hemorrhage</keyword>
	<keyword>Treatment</keyword>
	<keyword>MRI</keyword>
</DOC>